Generic versus Non-Generic Formulation of Extended-Release Clarithromycin in Patients with Community-Acquired Respiratory Tract Infections
Background and objective: There is a general concern about the use of multi-source (generic) antibacterials in the clinical setting with registration based solely on bioequivalence data. In order to address this concern, two modified-release formulations of clarithromycin (i.e. the originator Klacid XL® and the generic Klarithran MR®) were compared in patients with acute community-acquired respiratory tract infections.
Methods: Patients presenting with tonsillopharyngitis, sinusitis or pneumonia were randomized to receive either of the test drugs provided they clinically qualified for empirical clarithromycin treatment. The study endpoints were clinical and bacteriological cure rates, tolerability and safety. The study was designed to test for non-inferiority with regard to cure rates.
Results: The main outcome of this study was that both agents had similar clinical (non-inferior) and bacteriological cure rates and demonstrated no difference in tolerability in patients. The study also demonstrated the clinical efficacy of clarithromycin when used as empirical treatment in patients with respiratory tract infections in community practice (i.e. 95% clinical cure rate).
Conclusion: The clarithromycin extended-release multisource product (Klarithran MR®) does not differ significantly from the originator (Klacid XL®) and the clinical cure rate of the generic formulation is non-inferior to that of the originator. The two formulations are tolerated similarly.
KeywordsClarithromycin Sinusitis Clinical Cure Rate Moraxella Catarrhalis Bacteriological Cure
This study was sponsored by Ranbaxy Laboratories (SA) (Pty) Ltd.
Prof. Snyman, Prof. Grobusch, Dr Henning, Dr Rabie, Dr Hira, Dr Parshotam and Dr Mithal act as clinical research consultants to pharmaceutical companies, including Ranbaxy, in South Africa. Prof. Schoeman acts as a biostatistical consultant for the entire pharmaceutical industry in South Africa. Dr Singh and Mr Ramdas are employees of Ranbaxy (SA) (Pty) Ltd.
- 5.Feldman C, Brink AJ, Richards GA, et al. Management of community-acquired pneumonia in adults. S Afr Med J 2007; 97(12): 1296–306Google Scholar
- 8.Brink AJ, Working Group of the Infectious Diseases Society of Southern Africa. Guideline for the management of upper respiratory tract infections. S Afr Med J 2004 Jun; 94(6): 473–84Google Scholar
- 11.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 17th Informational Supplement 2007 January 27; 1: M100–S17Google Scholar
- 12.AIDS Clinical Trial Group. Table of grading severity of adverse experiences. Rockville (MD): Division of Aids, National Institute of Allergy and Infectious Diseases, 1996Google Scholar
- 18.Robinson DH, Narducci WA, Ueda CT. Drug delivery and administration. In: DiPiro JT, Talbert FL, Yee GC, editors. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford (CT): Appleton & Lange, 1999: 49–76Google Scholar
- 21.National Antimicrobial Surveillance Forum (NASF): South Africa, 2005Google Scholar